ProQR Therapeutics N.V. - Ordinary Shares (PRQR)
PRQR moved a median of -0.42% 30 minutes after news, and -1.96% by the close. How PRQR actually reacts to news — the realized, point-in-time move the market made, measured across 152 labeled events over the last three years with zero look-ahead.
PRQR’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 38% | 151 |
| 30-min | -0.42% | 41% | 152 |
| 60-min | -0.19% | 47% | 152 |
| to close | -1.96% | 33% | 151 |
| Middle 50% of PRQR reactions | -2.18% to +1.73% |
|---|---|
| Median reaction (30-min) | -0.42% |
| Measured reactions | 152 |
Half of all ProQR Therapeutics N.V. - Ordinary Shares news events land between -2.18% and +1.73% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How PRQR reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst upgrades | 22 | -0.09% | 50% | -3.48% |
| Analyst downgrades | 13 | +0.49% | 54% | -1.84% |
| Coverage initiations | 13 | +0.43% | 69% | -0.44% |
| Rating reiterations | 36 | +0.13% | 50% | -3.23% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how PRQR ranks against every other measured name →
That’s how PRQR usually reacts — get an email when it moves on news →Email me when PRQR moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to PRQR's baseline. Nothing else.
Recent PRQR events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 6-K ProQR Therapeutics N.V. For: Sep 23 | SEC filing · Form 6-K | SEC EDGAR | -0.27% | -10.05% | |
| ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor | Press release | GlobeNewswire | -0.27% | -10.05% | |
| Form 6-K ProQR Therapeutics N.V. For: Sep 09 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -2.93% | |
| ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026 | Press release | GlobeNewswire | +0.00% | -2.93% | |
| ProQR to Participate in Upcoming Investor Conferences in September 2026 | Press release | GlobeNewswire | +1.86% | +0.00% | |
| Form 6-K ProQR Therapeutics N.V. For: Aug 13 | SEC filing · Form 6-K | SEC EDGAR | -0.79% | -2.63% | |
| Form 6-K ProQR Therapeutics N.V. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | -0.79% | -2.63% | |
| ProQR Announces Second Quarter 2026 Operating and Financial Results | Press release | GlobeNewswire | -0.79% | -2.63% | |
| Form EFFECT ProQR Therapeutics N.V. | SEC filing · Form EFFECT | SEC EDGAR | -4.52% | -5.65% | |
| Form F-3 ProQR Therapeutics N.V. | SEC filing · Form F-3 | SEC EDGAR | -3.51% | -2.92% | |
| Form 6-K ProQR Therapeutics N.V. For: Jun 26 | SEC filing · Form 6-K | SEC EDGAR | +0.65% | -0.65% | |
| Form 6-K ProQR Therapeutics N.V. For: Jun 25 | SEC filing · Form 6-K | SEC EDGAR | -10.00% | -13.06% | |
| ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform | Press release | GlobeNewswire | -10.00% | -13.06% | |
| ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement | Press release | GlobeNewswire | -10.00% | -13.06% | |
| Form 6-K ProQR Therapeutics N.V. For: Jun 02 | SEC filing · Form 6-K | SEC EDGAR | -0.68% | +0.00% | |
| Form 6-K ProQR Therapeutics N.V. For: Mar 31 | SEC filing · Form 6-K | SEC EDGAR | -1.13% | +0.00% | |
| Form 6-K ProQR Therapeutics N.V. For: May 12 | SEC filing · Form 6-K | SEC EDGAR | -1.13% | +0.00% | |
| ProQR Announces First Quarter 2026 Operating and Financial Results | Press release | GlobeNewswire | -1.13% | +0.00% | |
| ProQR Announces Multiple Upcoming Scientific Conference Presentations Highlighting the Breadth of its Axiomer™ RNA Editing Platform | Press release | GlobeNewswire | -0.62% | -0.62% | |
| Form 6-K ProQR Therapeutics N.V. For: May 04 | SEC filing · Form 6-K | SEC EDGAR | +5.92% | +7.89% | |
| ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026 | Press release | GlobeNewswire | +5.92% | +7.89% | |
| Form 6-K ProQR Therapeutics N.V. For: Apr 30 | SEC filing · Form 6-K | SEC EDGAR | +0.97% | +1.29% | |
| ProQR Announces Nomination of Dr. Lykke Hinsch Gylvin to its Board of Directors | Press release | GlobeNewswire | +0.97% | +1.29% | |
| Form 6-K ProQR Therapeutics N.V. For: Apr 08 | SEC filing · Form 6-K | SEC EDGAR | -1.67% | +2.23% | |
| ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board | Press release | GlobeNewswire | -1.67% | +2.23% | |
| ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event | Press release | GlobeNewswire | +7.49% | +5.88% | |
| Form 6-K ProQR Therapeutics N.V. For: Mar 25 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | +3.95% | |
| ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026 | Press release | GlobeNewswire | +0.00% | +3.95% | |
| Form 20-F ProQR Therapeutics N.V. For: Dec 31 | SEC filing · Form 20-F | SEC EDGAR | -3.31% | -4.97% | |
| Form 6-K ProQR Therapeutics N.V. For: Mar 12 | SEC filing · Form 6-K | SEC EDGAR | -3.31% | -4.97% | |
| ProQR Announces Year End 2025 Operating and Financial Results | Press release | GlobeNewswire | -3.31% | -4.97% | |
| ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference | Press release | GlobeNewswire | +1.33% | +13.33% | |
| Form 6-K ProQR Therapeutics N.V. For: Feb 09 | SEC filing · Form 6-K | SEC EDGAR | -1.97% | -3.29% | |
| ProQR Announces Planned Changes to Board Composition | Press release | GlobeNewswire | -1.97% | -3.29% | |
| Form 6-K ProQR Therapeutics N.V. For: Jan 08 | SEC filing · Form 6-K | SEC EDGAR | +3.30% | -0.94% | |
| ProQR Announces Encouraging AX-0810 Phase 1 Safety and PK Data, Development Candidate Selections, and 2026 Outlook | Press release | GlobeNewswire | +3.30% | -0.94% | |
| ProQR to Participate in 8th Annual Evercore Healthcare Conference | Press release | GlobeNewswire | +2.61% | -7.83% | |
| Form 6-K ProQR Therapeutics N.V. For: Sep 30 | SEC filing · Form 6-K | SEC EDGAR | -0.42% | -4.33% | |
| ProQR Announces Third Quarter 2025 Operating and Financial Results | Press release | GlobeNewswire | -0.42% | -4.33% | |
| Form 6-K ProQR Therapeutics N.V. For: Nov 03 | SEC filing · Form 6-K | SEC EDGAR | +1.40% | -4.80% | |
| Form 6-K ProQR Therapeutics N.V. For: Oct 20 | SEC filing · Form 6-K | SEC EDGAR | +4.05% | +7.39% | |
| ProQR Receives CTA Authorization for AX-0810 and Announces Virtual Investor and Analyst Event on November 3, 2025 | Press release | GlobeNewswire | +4.05% | +7.39% | |
| ProQR to Participate in Upcoming Investor Conferences in October 2025 | Press release | GlobeNewswire | -1.22% | -7.29% | |
| Form 6-K ProQR Therapeutics N.V. For: Jun 30 | SEC filing · Form 6-K | SEC EDGAR | +0.00% | -0.48% | |
| ProQR Announces Second Quarter 2025 Operating and Financial Results | Press release | GlobeNewswire | +0.00% | -0.48% | |
| ProQR Announces Upcoming Presentation at RNA Editing Summit | Press release | GlobeNewswire | +1.36% | +1.82% | |
| Form 6-K ProQR Therapeutics N.V. For: Jun 26 | SEC filing · Form 6-K | SEC EDGAR | -0.91% | -7.27% | |
| ProQR Announces CTA Submission for Phase 1 Study of AX-0810 Targeting NTCP | Press release | GlobeNewswire | -0.91% | -7.27% | |
| Form 6-K ProQR Therapeutics N.V. For: Jun 03 | SEC filing · Form 6-K | SEC EDGAR | +1.11% | +0.56% | |
| ProQR Announces Upcoming Scientific Presentations at ASGCT and TIDES Conferences | Press release | GlobeNewswire | -0.31% | -2.45% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the PRQR section they belong to.
Where else PRQR is measured.
PRQR earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| MEI Pharma, Inc. (MEIP) | 152 | +0.07% | 51% |
| Milestone Scientific, Inc. (MLSS) | 152 | 0.00% | 50% |
| METASTAT INC (MTST) | 151 | 0.00% | 13% |
| CASI Pharmaceuticals, Inc. - Ordinary Shares (CASI) | 150 | +0.84% | 57% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ProQR Therapeutics N.V. - Ordinary Shares's median reaction calculated?
Every labeled PRQR news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 152 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 41% of PRQR's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does PRQR's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.